Request a Proposal  

Pharm-Olam Blog

Pharm-Olam Insights Blog

Pharm-Olam is a global CRO dedicated to helping you create a healthier world through the development of life-changing treatments. Here on our blog we will share our insights from recent studies, to interviews with industry leaders, investigators and patients.

John W Colby III

John is the head of marketing at Pharm-Olam, and has had the opportunity to see the industry from different perspectives over his 15 years; from proposals to sales, to operations and partnership oversight, to corporate strategy and marketing. When not on the job, you will probably find John out on the hiking trails with his wife and four young boys, enjoying the great outdoors.

Blog Feature

Pharm-Olam Insights | Infectious Disease & Vaccines

By: John W Colby III
January 13th, 2020

In this post, we discuss elements and lessons learned from a recent BARDA funded Influenza A Phase II study.  The study’s purpose was to assess the efficacy of the Sponsors IP in treating severely ill and hospitalized Influenza A patients. Subject Detail: The study was targeted to enroll a subset of the general Influenza A global population.  The study inclusion criteria required that each patient be ill for a certain number of days which could not be exceeded. The subject must also be hospitalized and specifically on oxygen therapy.

Blog Feature

Pharm-Olam Insights | "Rescue CRO"

By: John W Colby III
October 28th, 2019

Clinical Trials are large complex projects, and occasionally a sponsor may need to make a change to bring an underperforming project back on schedule. This type of change is not taken lightly by sponsors. Making such a transition takes time and a large investment in coordination and additional money. In this post, we will take you through a general scenario for a full-service contract research organization (CRO) transition. Our example will show when a sponsor fully transitions from the CRO currently running their study to a new CRO taking over and finishing it off. You may be wondering, “how long would that take?”. After reading this article, you will have the answer based on generally accepted timetables. 

GDPR_Checklist-cover

Join other Clinical Development experts to get the latest industry news, trends and insights.

As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist

Blog Feature

Rare & Orphan Disease

By: John W Colby III
August 13th, 2019

When working on a rare disease program, there are far reaching benefits to conducting a natural history (NH) study. In this article, Pharm-Olam's Dr. Jovana Vlajkovic-Josic was interviewed by Melissa Fassbender from Outsourcing-Pharma.